Community Practice Connections™: 1st Annual International Congress on the Future of Neurology®

Release Date: November 20, 2019
Expiration Date: November 20, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: 1st Annual International Congress on the Future of Neurology^® is a series of short video interviews and brief written content on clinical data pertaining to various neurologic disorders. The video interviews feature experts addressing relevant clinical data and questions commonly faced in the neurology practice setting in their respective fields.

Benefits of Participating

• Obtain a broad view of key topics in neurology
• Listen as experts in the field of neurology discuss new clinical data
• Learn something new in the field of neurology and improve your practice
• Sharpen your diagnostic expertise in the setting of neurologic disorders

Acknowledgement of Commercial Support

This activity is supported by educational grants from Akcea Therapeutics; Alder BioPharmaceuticals, Inc; Alnylam Pharmaceuticals, Inc; Eisai; Jazz Pharmaceuticals, Inc; Lilly; Mallinckrodt Pharmaceuticals; Mitsubishi Tanabe Pharma America, Inc; Portola Pharmaceuticals; Sarepta Therapeutics, Inc; SK Life Science, Inc; and Supernus Pharmaceuticals.

Target Audience

This activity is directed toward physicians who treat patients with neurologic disorders. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the management of patients with neurologic disorders are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Describe clinical strategies for diagnosing neurological disorders
• Identify current strategies and recent advancements in the treatment and prevention of neurological disorders
• Explain the mechanism of action of therapeutic agents used to treat neurological disorders
• Recognize and devise strategies to manage treatment-related adverse events in the setting of neurological disorders
• Outline multidisciplinary care and team communication strategies to optimize patient outcomes in the setting of neurological disorders
• Discuss recent clinical trial data in the context of its potential impact on the management of neurological disorders

Faculty, Staff, and Planners’ Disclosures

Faculty

Richard S. Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Memory Disorders Program
Assistant Dean of Faculty Development
Weill Cornell Medicine and NewYork-Presbyterian
New York, NY

Disclosures: no relevant financial relationships with commercial interests to disclose.

Fred Rincon, MD, MSc, MB. Ethics, FACP, FCCP, FCCM
Division Head, Cerebrovascular Disease – Farber Institute Neuroscience
Associate Professor of Neurology and Neurological Surgery
Sidney Kimmel Medical College at Thomas Jefferson University
Department of Neurological Surgery
Division of Critical Care and Neurotrauma
Philadelphia, PA

Disclosures: Consultant: Bard Pharmaceuticals; Speaker Bureau: Portola Pharmaceuticals; Other: NeurocCrit LLC founder.

Elizabeth A. Thiele, MD, PhD
Director, Pediatric Epilepsy Program
Director, Herscot Center for TSC
Massachusetts General Hospital
Professor of Neurology
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: GW Pharmaceuticals, Zogenix; Consultant: GW Pharmaceuticals, Zogenix, Biocodex, Aquestive, West Therapeutics, Upsher Smith.

John Brandsema, MD
Head, Neuromuscular Section
Director, Neuromuscular Education
Children’s Hospital of Philadelphia
Assistant Professor of Clinical Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: Alexion Pharmaceuticals, AveXis, Biogen, Cytokinetics, FibroGen, Pfizer, PTC, Sarepta Therapeutics; Consultant: Alexion Pharmaceuticals, AveXis, Biogen, Cytokinetics, Marathon Pharmaceuticals, PTC, Sarepta Therapeutics; Speaker Advisory Board: AveXis, Biogen.

Sami L. Khella, MD
Chief, Department of Neurology
Penn Presbyterian Medical Center
Professor of Clinical Neurology
Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosures: no relevant financial relationships with commercial interests to disclose.

Karl Doghramji, MD
Professor of Psychiatry, Neurology, and Medicine
Sidney Kimmel Medical College
Medical Director, Jefferson Sleep Disorders Center
Program Director, Sleep Medicine Fellowship
Thomas Jefferson University
Philadelphia, PA

Disclosures: Grant Research Support: Eisai, Harmony Biosciences, Inspire Pharmaceuticals; Consultant: Eisai, Harmony Biosciences, Jazz Pharmaceuticals, Merck, Pfizer, Teva Pharmaceutical Industries; Other: Shareholder: Merck.

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant Research Support: Actelion Pharmaceuticals, National Institutes of Health, National Multiple Sclerosis Society, Novartis, Sanofi; Consultant: Acorda Therapeutics, Actelion Pharmaceuticals, Atara Biotherapeutics, Apitope, Biogen, BrainStorm Cell Therapeutics, EMD Serono, GW Pharmaceuticals, Innate Immunotherapeutics, Jazz Pharmaceuticals, Mapi Pharma, MedDay Pharmaceuticals, MedImmune/Viela Bio, Novartis, Orion Biotechnology, Polpharma, Receptos/Celgene, Roche/Genentech, Sanofi Genzyme, Teva Pharmaceutical Industries, TG Therapeutics; Speakers Bureau: Sanofi (nonpromotional).

Jeffrey B. Ratliff, MD
Clinical Assistant Professor of Neurology
Associate Director, Neurology Residency Program
Director, Movement Disorders Fellowship
Comprehensive Parkinson’s Disease and Movement Disorders Center
A Parkinson’s Foundation Center of Excellence
Vickie and Jack Farber Institute for Neuroscience
Sidney Kimmel Medical College at Thomas Jefferson University
Jefferson Health
Philadelphia, PA

Disclosures: Grant Research Support: American Academy of Neurology Education Research Grant; Consultant: Acadia Pharmaceuticals; Speakers Bureau: Teva Pharmaceutical Industries, US WorldMeds.

William Young, MD
Professor of Neurology
Sidney Kimmel Medical College at Thomas Jefferson University
Jefferson Health
Philadelphia, PA

Disclosures: Grant Research Support: Amgen, Autonomic Technologies, Cumberland Pharmaceuticals, Eli Lilly, Novartis, Patient-Centered Outcomes Research Institute, Scion Pharmaceuticals, Teva Pharmaceutical Industries, Zosano Pharma; Consultant: Alder BioPharmaceuticals, Allergan, Amgen, Biohaven, Lilly, Promius Pharma, Theranica Bio-Electronics; Speakers Bureau: Lilly, Teva Pharmaceutical Industries.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, PER^® makes it a policy to ensure fair balance, independence, objectivity, and scientific rigor in all its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the companies that provided commercial support.